Showing 5851-5860 of 7779 results for "".
- FixMySkin Unveils New Lookhttps://practicaldermatology.com/news/fixmyskin-unveils-new-look/2458974/FixMySkin Healing Balms with 1% Hydrocortisone have a new look with the same great formula. Now available in environmentally friendly packaging, these balms come in two convenient sizes for the lips and body. Th
- Suneva Medical Introduces Regenica Recovery Gelhttps://practicaldermatology.com/news/suneva-medical-introduces-regenica-recovery-gel/2458983/Suneva Medical, Inc. introduced Regenica® Recovery Gel, a new addition to the Regenica® skin care system, during the American Academy of Dermatology Annual Meeting. Regenica® Recovery Gel is a soothing balm that is specially formulated to help quickly heal damaged skin. It infuses Mul
- Provectus Biopharmaceuticals' Novel Synthesis Patent Application Allowed by Chinese Patent Officehttps://practicaldermatology.com/news/provectus-biopharmaceuticals-novel-synthesis-patent-application-allowed-by-chinese-patent-office/2459017/Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company (
- derma e Launches Firming and Deep Wrinkle Productshttps://practicaldermatology.com/news/derma-e-launches-firming-and-deep-wrinkle-products/2459020/derma e® launched its new Firming DMAE Eye Lift and Deep Wrinkle Peptide Moisturizer SPF 30. “derma e® is raising the bar for natural skin care performance with the launch of these two new products,” says Jennifer Norman, Vice President of Marketing for derma e®. &
- Dermira and UCB Announce Start of Phase 3 Program for Cimzia® (Certolizumab Pegol) in Psoriasishttps://practicaldermatology.com/news/dermira-and-ucb-announce-start-of-phase-3-program-for-cimzia-certolizumab-pegol-in-psoriasis/2459027/Dermira, Inc., a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients (NASDAQ: DERM), and UCB, a global biop
- CMS Assigns Q-code to Fish Skin Technology, Kerecis Reportshttps://practicaldermatology.com/news/20141113-cms_assigns_q-code_to_fish_skin_technology_kerecis_reports/2459065/The new Omega3 tissue-regeneration material from Kerecis Limited—dubbed fish skin—has received a "Q" code from the Centers for Medicare and Medicaid Services (CMS). Kerecis Omega3 Wound, indicated for the management of chronic wounds including diabetic, vascular and other hard-to-heal wounds, has b
- New Book Launched: Cosmeceuticals and Cosmetic Ingredientshttps://practicaldermatology.com/news/20141113-new_book_launched_cosmeceuticals_and_cosmetic_ingredients/2459067/"Cosmeceuticals and Cosmetic Ingredients" (McGraw Hill), the second textbook from Dr. Leslie Baumann, is now available through Amazon.com and booksellers internationally. Written for medical and skincare students and professionals, "Cosmeceuticals and Cosmetic Ingredients" focuses on the scien
- Syneron Candela Announces FDA Clearance of PicoWay Picosecond Laser for Tattoo Removalhttps://practicaldermatology.com/news/20141103-syneron_candela_announces_fda_clearance_of_picoway_picosecond_laser_for_tattoo_removal/2459076/The FDA granted 510(K) clearance to Syneron Candela's PicoWay picosecond device for tattoo removal. PicoWay is a dual wavelength device, with 1064nm and 532nm wavelengths, which utilizes the proprietary PicoWay Technology to generate picosecond pulses for the removal of tattoos. The FDA clearanc
- SKINPACT Program Launched with New Global Awards Initiative to Support the Dermatology Communityhttps://practicaldermatology.com/news/20141010-skinpact_program_launched_with_new_global_awards_initiative_to_support_the_dermatology_community/2459088/Galderma, in partnership with the International League of Dermatological Societies, has started a search for initiatives that will fulfill an important role in strengthening the global dermatology community. Galderma launched a new global initiative un
- Galderma Initiates US Study of Novel Muscle Relaxant for Aesthetic Dermatology and Cosmetic Surgeryhttps://practicaldermatology.com/news/20141006-galderma_initiates_us_study_of_novel_muscle_relaxant_for_aesthetic_dermatology_and_cosmetic_surgery/2459095/Galderma has initiated a Phase II clinical trial of a novel muscle relaxant in the US. The Phase II clinical trial is a multicenter, dose-ranging study designed to evaluate the safety and effectiveness of Galderma's internally developed liquid form of botulinum toxin for the tre